ES2644423T3 - Anticuerpos humanos anti-receptor alfa de folato y fragmentos de anticuerpo para radioinmunoterapia de carcinoma de ovario - Google Patents

Anticuerpos humanos anti-receptor alfa de folato y fragmentos de anticuerpo para radioinmunoterapia de carcinoma de ovario Download PDF

Info

Publication number
ES2644423T3
ES2644423T3 ES07802280.3T ES07802280T ES2644423T3 ES 2644423 T3 ES2644423 T3 ES 2644423T3 ES 07802280 T ES07802280 T ES 07802280T ES 2644423 T3 ES2644423 T3 ES 2644423T3
Authority
ES
Spain
Prior art keywords
afra
antibody
fab
fragments
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07802280.3T
Other languages
English (en)
Spanish (es)
Inventor
Franck Martin
Margherita Cattozzo
Giovanni Maurizi
Vito Di Cioccio
Mariangela Figini
Silvana Canevari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Accelerator Applications SA
Fondazione IRCCS Istituto Nazionale dei Tumori
Original Assignee
Advanced Accelerator Applications SA
Fondazione IRCCS Istituto Nazionale dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications SA, Fondazione IRCCS Istituto Nazionale dei Tumori filed Critical Advanced Accelerator Applications SA
Application granted granted Critical
Publication of ES2644423T3 publication Critical patent/ES2644423T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES07802280.3T 2006-09-15 2007-09-12 Anticuerpos humanos anti-receptor alfa de folato y fragmentos de anticuerpo para radioinmunoterapia de carcinoma de ovario Active ES2644423T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06019399A EP1900752A1 (en) 2006-09-15 2006-09-15 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
EP06019399 2006-09-15
PCT/EP2007/007944 WO2008031577A1 (en) 2006-09-15 2007-09-12 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma

Publications (1)

Publication Number Publication Date
ES2644423T3 true ES2644423T3 (es) 2017-11-28

Family

ID=37737768

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07802280.3T Active ES2644423T3 (es) 2006-09-15 2007-09-12 Anticuerpos humanos anti-receptor alfa de folato y fragmentos de anticuerpo para radioinmunoterapia de carcinoma de ovario

Country Status (14)

Country Link
US (1) US8388972B2 (enExample)
EP (2) EP1900752A1 (enExample)
JP (1) JP5513114B2 (enExample)
KR (1) KR101497045B1 (enExample)
AU (1) AU2007296899B2 (enExample)
BR (1) BRPI0716811B8 (enExample)
CA (1) CA2662005C (enExample)
ES (1) ES2644423T3 (enExample)
IL (1) IL197300A (enExample)
MX (1) MX2009002711A (enExample)
NZ (1) NZ575093A (enExample)
RU (1) RU2464277C2 (enExample)
WO (1) WO2008031577A1 (enExample)
ZA (1) ZA200901328B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
CN105777907B (zh) * 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
EP2614084A4 (en) 2010-09-09 2014-02-19 Purdue Research Foundation HUMANE FOLAT RECEPTOR BETA ANTIBODIES AND METHOD FOR THEIR USE
SG189957A1 (en) * 2010-11-05 2013-06-28 Morphotek Inc Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
JP2014509841A (ja) 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
JP5881085B2 (ja) 2011-03-18 2016-03-09 国立大学法人 鹿児島大学 膵臓癌の治療用及び診断用の組成物
ES2661466T3 (es) * 2011-04-01 2018-04-02 Immunogen, Inc. Métodos para aumentar la eficacia de la terapia contra el cáncer con FOLR1
CN107011439B (zh) * 2011-07-15 2020-11-10 卫材R&D管理有限公司 抗叶酸受体α抗体及其应用
KR101870555B1 (ko) 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
US9629918B2 (en) 2012-02-29 2017-04-25 Purdue Research Foundation Folate receptor alpha binding ligands
SG11201500938XA (en) * 2012-08-31 2015-04-29 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
NZ717140A (en) 2013-08-30 2022-05-27 Immunogen Inc Antibodies and assays for detection of folate receptor 1
JP6463744B2 (ja) * 2013-10-08 2019-02-06 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫抱合体投薬レジメン
KR101646577B1 (ko) * 2014-08-14 2016-08-09 원광대학교산학협력단 엽산수용체 표적용 화합물 또는 이의 약학적으로 허용가능한 염과, 이를 유효성분으로 포함하는 암 예방, 진단 또는 치료용 조성물
SG11201704056XA (en) 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
RS61010B1 (sr) 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
ES2808853T3 (es) 2014-11-20 2021-03-02 Hoffmann La Roche Cadenas ligeras comunes y procedimientos de uso
CN122075735A (zh) 2015-09-17 2026-05-26 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
KR102584446B1 (ko) 2016-08-12 2023-10-04 엘.이.에이.에프. 홀딩스 그룹 엘엘씨. 알파 및 감마-d 폴리글루타메이트화 항엽산 및 이의 용도
WO2018031979A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
EP3706801B1 (en) 2017-11-08 2026-01-14 L.E.A.F Holdings Group LLC Platinum complexes and uses thereof
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
WO2019157129A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
CA3090391A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated raltitrexed and uses thereof
JP7491573B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化メトトレキセートおよびその使用
WO2019157133A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
CA3090384A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CA3090244A1 (en) * 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
CA3090875A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
US12290518B2 (en) 2018-02-14 2025-05-06 L.E.A.F. Holdings Group Llc Gamma polyglutamated methotrexate and uses thereof
CA3090943A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
US12048767B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
EP3765521A4 (en) 2018-03-13 2022-03-23 Phanes Therapeutics, Inc. ANTI-FOLATE RECEPTOR-1 ANTIBODIES AND USES THEREOF
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
SG11202111109UA (en) 2019-04-29 2021-11-29 Immunogen Inc Biparatopic fr-alpha antibodies and immunoconjugates
CA3149914A1 (en) 2019-08-06 2021-02-11 L.E.A.F. Holdings Group Llc Processes of preparing polyglutamated antifolates and uses of their compositions
CN111393528B (zh) * 2020-01-19 2023-01-31 中国药科大学 一种靶向叶酸受体α的单链抗体及其应用
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
EP4166569A1 (en) * 2021-10-18 2023-04-19 Fondazione IRCCS Istituto Nazionale dei Tumori Antibodies directed against alpha-folate receptor
CN117700557B (zh) * 2024-02-05 2024-04-30 卡秋(江苏)生物科技有限公司 一种特异性结合叶酸受体α的抗体或抗原结合片段
CN119757601A (zh) * 2025-01-06 2025-04-04 哈尔滨脉图精准技术有限公司 一种用于卵巢癌诊断的代谢标志物组合及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
CA2556027C (en) * 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
KR101461408B1 (ko) * 2005-10-06 2014-11-13 어드밴스드 엑셀러레이터 어플리케이션즈 에스.에이. 신규 선택 시스템

Also Published As

Publication number Publication date
RU2464277C2 (ru) 2012-10-20
JP2010503386A (ja) 2010-02-04
WO2008031577A1 (en) 2008-03-20
RU2009114161A (ru) 2010-10-20
AU2007296899A1 (en) 2008-03-20
MX2009002711A (es) 2009-06-18
EP2061813A1 (en) 2009-05-27
AU2007296899B2 (en) 2012-09-13
US8388972B2 (en) 2013-03-05
US20100055034A1 (en) 2010-03-04
JP5513114B2 (ja) 2014-06-04
WO2008031577A8 (en) 2009-07-02
NZ575093A (en) 2012-04-27
KR101497045B1 (ko) 2015-02-27
CA2662005A1 (en) 2008-03-20
CA2662005C (en) 2018-01-02
IL197300A0 (en) 2011-08-01
KR20090059114A (ko) 2009-06-10
ZA200901328B (en) 2010-05-26
EP2061813B1 (en) 2017-07-19
EP1900752A1 (en) 2008-03-19
BRPI0716811B8 (pt) 2021-05-25
IL197300A (en) 2016-02-29
BRPI0716811B1 (pt) 2020-11-24
BRPI0716811A2 (pt) 2013-11-05

Similar Documents

Publication Publication Date Title
KR101497045B1 (ko) 난소 암종의 방사성면역요법을 위한 인간 항-엽산염 수용체알파 항체와 항체 단편
US7090844B2 (en) Use of antibodies against the MUC18 antigen
ES2708124T3 (es) Procedimiento para preparar moléculas heteromultiméricas
ES2927090T3 (es) Anticuerpo anti-TROP-2 humano que muestra actividad antitumoral in vivo
WO2019024911A1 (zh) B7h3抗体-药物偶联物及其医药用途
ES2889398T3 (es) Anticuerpos anti-5T4 y conjugados de anticuerpo-fármaco
JP7539834B2 (ja) ガレクチン－３に対する抗体及びその使用方法
BRPI0809351A2 (pt) Anticorpo de anti cd166 humano ligando células tumorais humano
ES2923909T3 (es) Proteínas específicas para BAFF y B7RP1 y usos de las mismas
WO2019117684A1 (ko) a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도
JP2023545382A (ja) 抗体薬物複合体を含む医薬組成物及びその使用
CN113735974B (zh) 针对Claudin18.2的抗体及其用途
WO2022111476A1 (zh) 抗PD-L1-抗VEGF-抗TGF-β多特异性抗体、其药物组合物及用途
CN115501347A (zh) 抗her2抗体药物偶联物和parp抑制剂联合在制备治疗肿瘤的药物中的用途
TW202442681A (zh) 抗ror1抗體及其藥物偶聯物
KR20250042144A (ko) Itga2를 표적으로 하는 항체 및 이를 포함하는 항체-약물 접합체(antibody targeting itga2 and antibody-drug conjugate comprising the same)
EP4491632A1 (en) Ror1-targeted binding molecule and use thereof
JP6869553B2 (ja) デスレセプター４及びデスレセプター５に結合する非常に強力な抗体
US11834507B2 (en) Anti-MET agonist antibody for use in the treatment of colorectal cancer
WO2024213096A1 (en) Ceacam1-targeting antibodies and uses thereof
CA3254345A1 (en) Ror1-targeted binding molecule and use thereof
TW202543685A (zh) 抗體藥物偶聯物及其製備方法和用途
WO2025195495A1 (zh) 一种放射性核素偶联物及其制备方法和用途
CN120025446A (zh) 结合分子及抗体药物偶联物和用途
CN117756936A (zh) 一种Axl拮抗抗体或抗原结合片段